drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Half-life–extended bispecific T-cell engager (BiTE) antibody biologic that binds BCMA on malignant plasma cells and CD3 on T cells to redirect and activate cytotoxic T cells against BCMA-positive multiple myeloma cells; administered subcutaneously (± IV).
nci_thesaurus_concept_id
C147028
nci_thesaurus_preferred_term
Pavurutamab
nci_thesaurus_definition
A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of pavurutamab, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Half-life–extended bispecific T-cell engager antibody that binds BCMA on malignant plasma cells and CD3 on T cells, creating an immune synapse to redirect and activate cytotoxic T cells, leading to targeted lysis of BCMA-positive myeloma cells.
drug_name
AMG 701
nct_id_drug_ref
NCT04998747